SEARCH

SEARCH BY CITATION

References

  • 1
    Spence RK, Dafoe DC, Rabin G et al. Mycobacterial Infections in Renal Allograft Recipients. Arch Surg 1983; 118: 356359.
  • 2
    Bucci JR, Matsumoto CS, Swanson SJ et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13: 29742982.
  • 3
    Abbott KC, Oglesby RJ, Agodoa LY. Hospitalized avascular necrosis after renal transplantation in the United States. Kidney Int 2002; 62: 22502256.
  • 4
    Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42: 10581068.
  • 5
    Dye C, Scheele S, Dolin P et al. Global burden of tuberculosis estimated incidence, prevalence and mortality by country. JAMA 1999; 282: 677686.
  • 6
    Sleasman JW. The association between immunodeficiency and the development of autoimmune disease. Adv Dent Res 1996; 10: 5761.
  • 7
    Hill N, Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol 2002; 14: 791797.
  • 8
    Kasiske BL, Ramos EL, Gaston RS et al. The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1995; 6: 134.
  • 9
    Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11: S1S86.
  • 10
    American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49: 154.
  • 11
    Smirnoff M, Patt C, Seckler B, Adler JJ. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998; 113: 2527.
  • 12
    Woeltje KF, Mathew A, Rothstein M, Seiler S, Fraser VJ. Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 1998; 31: 848852.
  • 13
    Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002; 347: 18601866.
  • 14
    Sester M, Sester U, Clauer P et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int 2004; 65: 18261834.
  • 15
    Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27: 12661277.
  • 16
    Apaydin S, Altiparmak MR, Serdengecti K, Ataman R, Ozturk R, Erek E. Mycobacterium tuberculosis infections after renal transplantation. Scand J Infect Dis 2000; 53: 501505.
  • 17
    Poduval RD, Hammes MD. Tuberculosis screening in dialysis patients – is the tuberculin test effective Clin Nephrol 2003; 59: 436440.
  • 18
    Kaufman D, Koffron A. Renal Transplantation (Medical). http://www.emedicine.com/med/topic2604.htm, 2004.
  • 19
    Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant 2002; 16: 18.
  • 20
    Pascual-Ramos V, Hernandez-Cruz B, Villalobos I, Sifuentes-Osornio J, Alcocer-Varela J. Purified protein derivative reaction in systemic lupus erythematosus patients. Indirect study of cellular immunity. Lupus 2002; 11: 2530.
  • 21
    Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 32703277.
  • 22
    Antony SJ, Ynares C, Dummer JS. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transplant 1997; 11: 3437.
  • 23
    Eastwood JB, Corbishley CM, Grange JM. Tuberculosis and the kidney. J Am Soc Nephrol 2001; 121: 307314.
  • 24
    EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV, Long-term management of the transplant recipient. IV, 7.2. Late infections. Tuberculosis. Nephrol Dial Transplant 2002; 17 (Suppl. 4): S3943.
  • 25
    Freitag VL, Skifton RD, Lake KD. Effect of short-term rifampin on stable cyclosporine concentrations. Ann Pharmacother 1999; 33: 871872.
  • 26
    Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453457.
  • 27
    Lattes R, Radisic M, Rial M, Argento J, Casadei D. Tuberculosis in renal transplant recipients. Transpl Infect Dis 1999; 1: 98104.
  • 28
    Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 9196.
  • 29
    Chenhsu RY, Loong CC, Chou MH, Lin MF, Yang WC. Renal allograft dysfunction associated with rifampin–tacrolimus interaction. Ann Pharmacother 2000; 34: 2731.